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The Working Group on Neurogenic Inflammation proposed 11 testable hypotheses in the three
domains of neurogenic inflammation, perceptual and central integration, and nonneurogenic
inflammation. The working group selected the term people reporting chemical sensitivity (PRCS)
to identify the primary subject group. In the domain of n6urogenic inflammation, testable hypothe-
ses included: PRCS have an increased density of c-fiber neurons in symptomatic tissues; PRCS
produce greater quantities of neuropeptides and prostanoids than nonsensitive subjects in response
to exposure to low-level capsaicin or irritant chemicals; PRCS have an increased and prolonged
response to exogenously administered c-fiber activators such as capsaicin; PRCS demonstrate
augmentation of central autonomic reflexes following exposure to agents that produce c-fiber
stimulation; PRCS have decreased quantities of neutral endopeptidase in their mucosa;
exogenous neuropeptide challenge reproduces symptoms of PRCS. In the domain of perceptual
and central integration, testable hypotheses included: PRCS have alterations in adaptation,
habituation, cortical representation, perception, cognition, and hedonics compared to controls; the
qualitative and quantitative interactions between trigeminal and olfactory systems are altered in
PRCS; higher integration of sensory inputs is altered in PRCS. In the domain of nonneurogenic
inflammation, testable hypotheses included: increased inflammation is present in PRCS in
symptomatic tissues and is associated with a heightened neurosensory response; PRCS show an
augmented inflammatory response to chemical exposure. The working group recommended that
studies be initiated in these areas. - Environ Health Perspect 105(Suppl 2):531-537 (1997)
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Introduction
The goal of the Working Group on symptoms in people reporting chemical
Neurogenic Inflammation was to formu- sensitivities. The working group designated
late specific testable hypotheses to explain people reporting chemical sensitivity
the relationship between exposure and (PRCS) as the phrase to identify the group
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ofprimary interest. For specific research
projects, the working group emphasized
the importance of certain hypotheses,
clearly stated subject selection criteria, uni-
form subject characterization methods, and
inclusion ofappropriate controls.
The group identified three broad
domains in which hypotheses could be
generated: neurogenic inflammation, per-
ceptual and central integration, and
inflammation. Neurogenic inflammation
was the initial assigned task ofthe group.
However, some group members thought
perceptual and central integration or non-
neurogenic inflammation likely were the
domain ofprimary dysfunction. Figure 1
indicates the likely interactions between
these three domains.
The working group focused on under-
standing symptoms and processes that
occur minutes, hours, or days after low-
level chemical exposure. The group limited
experimental questions to those that could
be performed using existing methods and
techniques. In the future techniques such
as functional imaging may be useful but
are insufficiently developed at present.
Reagents for immunohistochemistry and
immunoassays, and pharmacologic agents
for human use are also developing rapidly.
The group thought individual research
groups should specify their own definitions
ofchemical sensitivity but draw from pre-
viously proposed definitions. Subjects with
diagnosed diseases may be included in
research if controls include diseased sub-
jects with and without chemical sensitivity.
Studies may include subject groups with
rhinitis and asthma, for which measures of
short-term responses are well developed.
Subjects with known psychiatric disease
may also be included.
This paper presents definitions and
general considerations for experimental
Chemical
sensitivity
Neurogenic Inflammation
inflammation
Perceptual
and central
integration
Figure 1. Potential interactions between chemical sen-
sitivity and the domains of neurogenic inflammation,
perceptual and central integration, and nonneurogenic
inflammation.
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design and methods, followed by consider-
ations specific to the domains ofneurogenic
inflammation, perceptual and central inte-
gration, and inflammation. Also included
are the rationale for potential involvement
of the domain, specific hypotheses, and
selected references.
Definitions
People reporting chemical sensitivity:
The primary research subject group. The
term multiple chemical sensitivity (MCS)
or MCS-syndrome can be used as a
research term provided there is an explicit
research definition. The phrase chemical
sensitivity may reflect several alterations in
exposure-response relationships. Figure 2
illustrates terminology. The terms have
been chosen because committee members
thought they had common usage across
disciplines ofphysiology and psychology.
Irritation: An excessive response to
stimulation, i.e., specifically a condition of
soreness or inflammation. Many chemicals
stimulate c-fiber nerves; patients report
having excessive responses. At present, it is
unknown whether the response is charac-
terized by soreness (acute discomfort) or
induction ofinflammation.
Increased response: An inclusive term
that can mean increased sensitivity, increased
reactivity, andprolonged duration.
Increased sensitivity: A leftward shift
in the exposure-response curve.
Increased reactivity: An increase in the
slope or the maximum of the exposure-
response curve.
Increased duration: An increase in the
duration ofthe response.
Threshold for symptoms: The point
on the exposure-response curve at which
symptoms are reported by the subject.
Habituation: Over time, the repeated
presentation ofa stimulus elicits a response
ofdiminished amplitude.
Adaptation: The tendency, characteris-
tic of a sensory organ, to show a dimin-
ished response as a result ofprolonged or
short-term repetitive stimulation.
Peripheral neural pathways: Peripheral
nerves innervating organs contain both
afferent and efferent neural pathways.
Chemosensitive c-fiber nerves are afferent
nerves that may have efferent functions
through the axon reflex (Figure 3). Neuro-
peptides contained in c-fiber nerves include
substance P (sub P), calcitonin gene-related
peptide (CGRP), and neurokinin A
(NKA). Efferent nerves include the sympa-
thetic nerves and parasympathetic nerves.
Sympathetic neurotransmitters include
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Figure 2. Illustration ofterminology. (A) More sensitive denotes a decrease in the magnitude of exposure required
to initiate the response; more reactive denotes an increase in the slope or in the maximum level of the
exposure-response curve. (B) The threshold for perceiving symptoms may occur in the mid-position of the expo-
sure-response curve (T). As a result, the clinical report of increased sensitivity could mean that the individual has
become more reactive (R) or more sensitive (S). (C) Recognition of symptoms may requirethatthe response be pre-
sent for a certain duration. The clinical report of increased sensitivity could mean that the response has become
more prolonged. (D) Habituation is the decrease in the amplitude of the response that occurs with repeated pre-
sentation of a stimulus. Adaptation is a progressive decrease in the magnitude of the response with prolonged
presentation of a stimulus. The term adaptation is sometimes used to describe both adaptation and habituation, as
defined above.
norepinephrine (Nor) and neuropeptide Y
(NPY). Parasympathetic nerves contain
acetylcholine and vasoactive intestinal pep-
tide (VIP). The importance ofeach neural
pathway in overall organ function or specific
cell function depends on the densityofnerve
fibers, proximity to target sites, and the pres-
ence ofspecific receptors on target tissues.
Trigeminal nerve: The trigeminal
nerve innervates the face and divides into
the ophthalmic, maxillary, and mandibular
branches (1). The trigeminal nerve inner-
vates the respiratory mucosa that first con-
tact inhaled irritants. The trigeminal nerve
contains afferent and efferent nerves. Upper
respiratory tissue is densely innervated with
c-fiber nerves in the epithelium, glands,
and vessels (1). Neuropeptide receptors are
widespread in mucosal tissues. Efferent
cholinergic fibers typically stimulate glan-
dular secretion, whereas adrenergic fibers
altervascular tone.
Neurogenic inflammation: Neurogenic
inflammation is initiated by stimulation of
peripheral c-fiber neurons (2-4) (Figure 3).
Aperipheral axon reflex results in the release
ofneuropeptides and in signs ofinflamma-
tion at a peripheral sites distinct from the
site ofthe original stimulus. The stimulus is
also transmitted centrally and provides a
central afferent signal and efferent reflexes.
Perceptual and central integration:
Perceptual and central integration describes
the process by which peripheral stimuli are
delivered, processed, and interpreted by the
central nervous system. Anatomic elements
of central representation include primary
and secondary projection and association
areas. Functional elements ofperceptual
and central integration include quality cod-
ing, intensity, cognitive (discrimination),
hedonic evaluation, and integration of
information from other sensory receptors.
Inflammation: Inflammation is a
dynamic process that may be initiated by
diverse stimuli (e.g., allergen, infection,
injury) and is characterized by diverse fea-
tures (e.g., degree ofedema, dominant cell
type, degree ofstructural tissue alteration),
and diverse sequelae (complete resolution,
chronic inflammation, resolution with
scarring). Typical features ofinflammation
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Figure 3. Anatomic elements of the response to chemosensitive nerve stimulation. Stimulati
nerves results in a peripheral axon reflex with release of neuropeptides sub P, CGRP, and NKA. T
may be inactivated by neutral endopeptidase, an enzyme present in the mucosa, or may bind to
on the epithelium, glands, smooth muscle, or vessels. Stimulation of the nerves may also result
ent stimulus, with activation of parasympathetic nerves and sympathetic nerves. The neurotran,
nerves are Ach and VIP (parasympathetic) and Norand NPY (sympathetic).
are rubor (erythema, vasodilatation), calor
(heat), turgor (edema), dolor (pain), and
loss offunction.
Experimental Design
and Methods
SubjectSelection
People reporting chemical sensitivity have
signs or symptoms associated with expo-
sures to a group ofcommonly encountered
chemical inhalants such as products of
combustion, cleaning products, pesticides,
perfumes, and fragrances at levels encoun-
tered in daily life. The symptoms occur in
one or more organ systems and often in
many organs. Several research definitions
encompassing these features have been
published (5-7). Although no single case
definition was endorsed by the work group
participants, there was agreement that dif-
ferent selection criteria would be necessary
for different studies, that chemically sensi-
tive patients are aheterogeneous group, and
subgroups might be selected in particular
experiments. For example, subjects could be
recruited on the basis of their dominant
symptoms (neurocognitive, respiratory). A
distinct onset ofsensitivity with an identifi-
able exposure is not necessary for inclusion
(as proposed by Cullen), and patients with
insidious as well as acute onset ofsensitivity
symptoms may be studied.
Subjects with diagnosed
be included in research if c(
include diseased subjects witi
chemical sensitivity (Table
diagnostic criteria or researc
for many diseases are publi.
may include subject groups
and asthma, for which meas
term responses are well deve
association with which chem
is commonly reported.
Subject Characterization
Characterization may include
and pattern of onset of syn
insidious vs abrupt), the sub
tion of the cause of sympto
cific stressor(s)], current fun
employment status, and cur
legal issues (if any). The use
questionnaires will assist in
between studies.
Ethical Consideratiol
and Protection of
Human Subjects
Confidentiality
National Institute for Drug
certificates of confidentialit
that accumulates informatic
tially sensitive nature about
information derived in the
not discoverable in medico-legal proceed-
ings. Because ofthe complex medico-legal
0 context of chemical sensitivity problems,
Q @3 investigators are encouraged to consult
with this agency and to consider requesting
a certificate ofconfidentiality.
Laryngeal Protection ofSubjects
muscles All protocols should be reviewed and
approved by the local Institutional Review
Board and written consent obtained for
controlled exposures. Subjects typically are
monitored by laboratory scientists and
remain within voice reach during exposure
sessions. Subjects are instructed in how to
oe ask for help or to remove themselves from
exposure and assured that they may
promptly remove themselves from exposure
at any time.
EEposure Conditions
zion of the c-fiber E. Co.iton
*he neuropeptides Human exposure facilities allow careful
receptors present control of the circumstances of exposure.
in a central affer- The principle of using exposures equiva-
smitters for these lent to ambient exposures should be fol-
lowed in establishing exposure regimens
for people reporting chemical sensitivity.
Attention should be given to the speci-
diseases may ficity ofthe stimulus. For example, studies
ontrol groups have established that some agents act as
h and without selective trigeminal or olfactory stimuli.
1). Standard Blinding or masking may or may not be
:h definitions possible; interpretation of study results
shed. Studies should consider the potential for bias in
with rhinitis unmasked challenges (8).
;ures ofshort- Another use ofcontrolled human expo-
cloped and in sure facilities is to examine the effect of
ical sensitivity removing agent exposures (e.g., filtering the
air, removing point sources, providing spe-
cial diets). Aswith exposure studies, interpre-
tation ofstudy results should consider the
e the duration potential forbias in unmasked challenges.
niptoms (e.g., MoirngRs ject's percep- Monito Risk
ms [e.g., spe- Pilot studies are appropriate with subse-
ctional status, quent review to determine whether the risks
rrent medico- are as predicted for people with chemical
of published sensitivity. The principal investigator should
comparisons closely monitor the responses ofstudy sub-
jects to determine whether typical symptoms
ns
are being elicited or whether a previously
unknown adverse response is occurring.
ChoiceofChemical forChalienges
The choice ofchemical for the challenge
exposures should take into consideration
Abuse issues the portion ofthe respiratory tract where
y for research deposition ofthe chemical and interaction
in of a poten- with the respiratory tract occur. For exam-
a subject. The ple, it is well known that water-soluble
study is then volatiles deposit almost exclusively in the
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nasal passages (9). Formaldehyde is perhaps
one ofthe best examples ofa chemical that
because of its reactive, water-soluble prop-
erties is deposited primarily in the nasal
cavity and interacts with components ofthe
nasal mucosa (10,11). Thus, on inhalation
challenge the effects offormaldehyde should
be directly related to initial interactions
within this respiratory tract region. Water-
soluble alcohols and ethers will also be
deposited in the nasal passages; these chemi-
cals can interact with specific receptors in
the nasal mucosa, thereby initiating poten-
tial toxic effects or adverse responses. In
contrast, water-insoluble volatiles are not
entrained by the nasal mucosa and would
therefore continue down the airways to be
deposited in more distal regions (9).
Ozone is an example ofa reactive chem-
ical that will be deposited throughout the
respiratory tract (12). However, because of
regional anatomical and histologic differ-
ences, it reacts with respiratory mucosa pri-
marily in the region ofthe nasal transitional
epithelium and the respiratory bronchioles.
Thus, effects on challenge with ozone
should be either of an anterior nasal or a
lower respiratory tract nature (13,14).
Finally, nonreactive water-insoluble
organics will continue to the most distal
portions of the respiratory tract and be
absorbed into the blood because ofthe high
perfusion of the alveoli. These types of
chemicals, xylene, toluene, and hexane, for
example, will be translocated in the blood to
various targets in the central nervous system,
including the brain. Complex mixtures such
as cigarette smoke, gasoline exhaust, and
diesel combustion products contain exam-
ples of each of the chemical classes listed
above (15). Thus, these complex mixtures
would be expected to exhibit upper and
lower respiratory effects as well as distal cen-
tral nervous system effects. The advantage of
these complex mixtures is that they repro-
duce environmental stimuli that patients
identify as triggers ofsymptoms.
Removal from exposure is also an inter-
vention that may aid in understanding the
disease process. An example of a question
that could be posed using a unit is: Does
residence in an environmental unit reduce
indices of inflammation in patients with
diseases known to be characterized by
chronic inflammation?
Experimental Reagents
and Methods
Experimental reagents and methods define
the practical boundaries ofexperimentation
and hypothesis testing. The committee
Table 1. Approach to selection of subjects and controls: disease, structure, and function.
Subject reports Subject does not report
chemical sensitivity, chemical sensitivity,
PRCS+ PRCS-
Disease
Diagnosable disease present, Dis +
Diagnosable disease absent, Dis -
Structure
Histologic feature present, Path +
Histologic feature absent, Path -
Function
Specific function or response present, Response +
Specific function or response absent, Response -
Table 2. Established outcome measures.
Structural/mediator Functional
Physical examination Patency, erythema, edema, heat Range of motion
End organ structure orfunction Acoustic rhinometry (29) Rhinomanometry
Computerized tomography Pulmonary function test
Magnetic resonance imaging Mucociliary clearance (30)
Smell identification test (31)
Neurocognitive batteries
Presence of edema Histology: endothelial gaps Increased resistance to flow,
Albumin (32,33) tissue turgor
Kinins
Reduced/abnormal airway Pathology offast-frozen specimens, Tear film breakup (35)
surface fluid disc weight (34)
Vasodilatation Quantification ofvascular area, Congestion reversed with
redness, temperature vasoconstrictors (36)
Inflammatory cell influx Acute inflammatory cell influx (37)
Chronic inflammatory cell influx
Proinflammatory mediators Cytokines
Neuropeptides
Structural changes Basement membrane thickening
Altered nerve density, tissue
neuropeptide content(38-41),
or neuropeptide receptors
Epithelial integrity Tracer uptake (42) Mucosal transepithelial
potential difference (43)
Functional responsiveness Reactivity to challenge (29,33,34)
Negative mucosal potential (20)
Central processing Trigeminal evoked potentials (19)
Olfactory evoked potentials (21)
primarily considered outcome measures
that have previously been used in studies
involving human subjects. Table 2 lists
such measures, but the working group
emphasized that each outcome measure
should be proposed for use only in the con-
text ofa defined hypothesis, adequate ratio-
nale, and experimental design. Additionally.
the need for new, objective outcome mea-
sures was recognized.
Domain 1: Neurogenic Inflammation
Neurogenic inflammation is a subset
ofinflammation but is given special atten-
tion in this paper, since it is initiated by
stimulation of chemosensitive c-fiber
nerves. People reporting chemical sensitiv-
ity typically report that their symptoms are
triggered by exposure to diverse chemicals.
The structural diversity ofagents initiating
symptoms makes an allergic etiology
unlikely, but structurally diverse chemicals
do stimulate the irritant receptor (16).
When agents stimulate c-fiber nerves, they
may initiate an axon reflex, central processes
(Figure 3), and sympathetic and parasym-
pathetic reflexes.
The broad hypothesis is that the
chemosensitive nerves, their products, and
their receptors, are the critical end organs
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in chemical sensitivity syndromes (17).
Alterations in neurogenic inflammation
could occur at the afferent irritant recep-
tor in the control of the axon reflex (such
as the density of nerve fibers, their neu-
ropeptide content, the quantity of neu-
ropeptide released with simulation, and
the area of release resulting from stimula-
tion). Alterations could also occur at the
level ofthe tissue neuropeptide receptor or
intracellular transduction of the receptor
stimulus (Figure 3). Alterations could also
occur in central processing of the irritant
stimulus (see "Domain 2: Perceptual and
Central Integration") and in the control or
expression ofautonomic reflexes. Cell- and
plasma-derived mediators generated during
infectious or allergic inflammation may
modulate neurogenic inflammation.
There are two versions of the neuro-
genic inflammation hypothesis. One
hypothesis states that the inciting event or
process is unknown. Once the process
begins, the c-fiber nerves play a central role
in the increased sensitivity and decreased
specificity of responses as well as relay to
and amplification ofcentral reflexes. The
adverse reaction to an exposure reflects the
severity of the process, but the low-level
chemical exposure does not materially alter
the pathologic process. A separate hypothe-
sis states that the initiating process for
chemical sensitivity is chemically induced
injury to the c-fiber neuron structure and
function, and that the course and severity
ofthe syndrome are a function ofthe mag-
nitude of continuing exposure to the
chemical, with injury progressing with
low-level, symptom-inducing exposures.
Airborne chemicals can activate the sen-
sory irritant receptor through two different
mechanisms (16). First, the receptor can be
activated by physical adsorption, which is
believed to be the case for alkanes, alkylben-
zenes, alcohols, ketones, and ethers. The
alkylbenzenes activate the receptors via a
benzene binding site and the alcohols acti-
vate the receptor via a hydrogen bond.
Capsaicin, the active ingredient in red pep-
per, binds to the vanilloid receptor. Second,
the other group ofsubstances activates the
receptor by a chemical reaction (16). In
general, this group of substances is more
potent than substances only physically
adsorbed to the receptor. The chemically
reactive substances can break a disulfide
bond in the receptor, which is believed to
be the mechanism by which sulfur dioxide
activates the receptor. Many substances
activate the receptor by a chemical reaction
with a nucleophilic group.
Formaldehyde, acrolein and related
substances, and chlorobenzylidene mal-
ononitriles and related substances all are
expected to react with a thiol group in the
receptor. Oxidizing agents such as chlorine
and ozone may oxidize the thiol group and
thereby activate the receptor. The thiol
group might also be involved in the acid-
based reactions responsible for the receptor
activation process of amins. Other nucle-
ophilic groups (HO- or NH2 groups) may
be involved in the binding of isocyanates
and some ofthe aldehydes.
c-Fiber nerves contain and release biolog-
ically active neuropeptides. Neuropeptides
have been shown to influence the function
of immune effector cells and epithelial
structures such as epithelium, glands, and
vessels. The presence and activity of
neuropeptide receptors at tissue sites are
important in determining the conse-
quences of neuropeptide release (1).
Enzymes that degrade neuropeptides, for
example, neutral endopeptidase, are pre-
sent in airway epithelium and may be
oxidatively inactivated by tobacco smoke
exposure (18) In addition to the periph-
eral axon reflex, concomitant generation of
an afferent signal to the central nervous
system typically occurs, stimulating central
processes and autonomic reflexes (3).
Neurogenic InflammationHypotheses
GeneralHypothesis. The structure of the
c-fiber system and function ofthe neuroin-
flammatory system is altered in people
reporting chemical sensitivity.
* People reporting chemical sensitivity
have an increased density of c-fiber
neurons in tissues where increased sen-
sitivity is reported.
* People reporting chemical sensitivity
produce greater quantities ofneuropep-
tides and prostanoids than nonsensitive
subjects in response to exposure to low-
level capsaicin or irritant chemicals.
* People reporting chemical sensitivity
have increased and prolonged responses
to exogenously administered c-fiber
activators such as capsaicin, as measured
by the symptoms, negative mucosal
potential, transepithelial potential dif-
ference, products ofglandular secretion
or plasma exudation, or mucociliary
clearance.
* People reporting chemical sensitivity
demonstrate augmentation of central
autonomic reflexes following exposure
to agents that produce c-fiber stimula-
tion. For example, trigeminal reflexes
are altered in the maxillary and
ophthalmic branches, as evidenced by
the CO2 threshold and/or dose-
response function in the nose or eye.
* People reporting chemical sensitivity
are less able to inactivate endogenously
released neuropeptides because they
have decreased quantities of neutral
endopeptidase in their epithelium.
Agents that alter neutral endopeptidase
metabolism alter the symptomatic or
objective responses to agent exposure.
* Administering exogenous neuropep-
tides to PRCS reproduces their symp-
toms. Activation of the neuropeptide
receptor signal transduction process
and the transduction process itself is
altered in PRCS.
* Residence in an environmental unit
alters the threshold or dose-response to
c-fiber stimulation in subjects with
chemical sensitivity.
Domain 2: Perceptual and
Central Integration
Perceptual and central integration is
thought to be altered in PRCS for two rea-
sons. First, PRCS commonly complain of
alterations in cognitive function. These
complaints worsen with exposures but may
be present to a lesser extent at baseline.
Localization to the central nervous system
of exposure-induced symptoms suggests
that processes involved with perception or
the integration of perception with cogni-
tive functions may be affected. The second
reason is that the central nervous system
processes are an integral part ofthe response
to a sensory stimulus such as an irritant or
an odor (19-24). Anatomic elements of
central representation include primary
and secondary projection and association
areas. Functional elements include quality
coding, intensity, cognitive discrimination,
hedonic evaluation, and integration of
other sensory receptors. Understanding
central processes may suggest rational
pharmacotherapy (25).
Central andPerceptual
Integration Hypotheses
Sensory information processing systems
are altered in people reporting chemical
sensitivity.
* Patients reporting chemical sensitivity
have alterations in adaptation, habitua-
tion, cortical representation, percep-
tion, cognition and hedonics.
* Adaptation or habituation to repeated
chemosensitive stimulation differs
between patients with chemical sensi-
tivity and controls.
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Habituation refers to the tendency
for the amplitude of a response to
diminish over time with repeated pre-
sentation ofthe stimulus that elicits the
response. The reflexes referred to in the
neurogenic inflammation section could
habituate or fail to do so in patients
reporting chemical sensitivity. In these
patients, the reflexes might even become
sensitized or show increased reactivity.
Adaptation, in this context, refers to
a sensory organ's tendency to show a
diminished response as a result ofpro-
longed or repeated stimulation. As a
result, perception becomes less salient
or appears to be less intense. For exam-
ple upon entering a room containing an
odorant, an individual may perceive an
odor to be very strong. Fifteen to thirty
minutes later, the odor may be barely
noticeable. Chamber studies indicate
odor adaptation is strong, reaching per-
haps 60% (26,27). Synergy may occur
for irritation when exposure to mixtures
occurs (28). Sensory irritation, however,
shows much less adaptation. People
reporting chemical sensitivity may fail to
have sensory adaptation or even may
have the occurrence of sensitization.
Sensitization, in the neurotoxicology
field, refers to the development of an
augmented response as a result ofpro-
longed or repeated stimulation.
* The qualitative and quantitative inter-
actions between trigeminal and olfac-
tory systems are altered in people
reporting chemical sensitivity. Both
peripheral and central interactions
should be considered.
* Higher integration ofsensory inputs is
altered in PRCS.
Domain 3: Inflammaion
People reporting chemical sensitivity
report exposure-induced symptoms per-
sisting for hours to days. Constitutional
symptoms such as malaise and fatigue
suggest the induction of an inflammatory
response. Experimental methods exist to
obtain objective evidence for an inflamma-
tory response. Cellular response may
include polymorphonuclear leukocytes,
lymphocytes, mast cells, eosinophils, and
macrophages, whereas the biochemical
response can be assessed by measuring
serum- or tissue-derived mediators or pro-
teins. There may or may not be evidence
for tissue injury at the site ofinflammation.
Inflammation Hypotheses
Increased inflammation is present in
PRCS, and may be found in the eyes,
upper and lower airway, gastrointestinal
tract, skin, vascular system, and joints.
* People reporting chemical sensitivity
have heightened inflammatory responses
to chemical exposure. This heightened
response could be due to physiological
and/or anatomical alterations. The tem-
poral relationship between exposures to
chemicals and the onset of inflamma-
tion reflects the subject's typical expo-
sure-response history.
* Indices of inflammation will resolve
with uniform avoidance of stressors,
including chemical, physical, emo-
tional, and nutritional stressors, and
sleep deprivation.
* The heightened neurosensory response
to chemicals in PRCS is associated with
the degree of inflammation present at
the time of exposure. Pharmaceutical
agents that target inflammation will
reduce the neurosensory response to
irritant chemicals.
* The inflammatory response to chemi-
cals is modified by acute and chronic
exposure to chemicals.
Summary and
Recommendations
It is reasonable to hypothesize that
neurogenic inflammation, perceptual and
central integration, and inflammation are
involved in the pathogenesis of chemical
sensitivity symptoms. Research is recom-
mended to test the hypotheses outlined in
this report.
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